ResearcherSamsung Medical CenterActive in the last 2 years
Seung Tae Kim
Matched on ORCID iD 0000-0001-7335-1846; OpenAlex author ID A5026351538, A5113847464. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 6
- L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. First author DOI 10.1038/s41598-025-07668-1↗
- Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Co-author DOI 10.1177/17588359211038478↗
- Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korea… Co-author DOI 10.1177/1758835919871126↗
- Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. Co-author DOI 10.1186/s12885-018-4995-0↗
- Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Co-author DOI 10.1097/coc.0b013e31821a83d7↗
- Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Co-author DOI 10.1158/1535-7163.mct-11-0269↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joon Oh Park · 6 shared papers, 2011–2025 · strength 0.61
- Paper L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. DOI 10.1038/s41598-025-07668-1↗
- Paper Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. DOI 10.1177/17588359211038478↗
- Paper Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. DOI 10.1186/s12885-018-4995-0↗
- Young Suk Park · 5 shared papers, 2011–2025 · strength 0.53
- Paper L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. DOI 10.1038/s41598-025-07668-1↗
- Paper Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. DOI 10.1177/17588359211038478↗
- Paper Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. DOI 10.1186/s12885-018-4995-0↗
- Jung Yong Hong · 2 shared papers, 2021–2025 · strength 0.40
- Kee‐Taek Jang · 3 shared papers, 2011–2025 · strength 0.32
- Paper L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. DOI 10.1038/s41598-025-07668-1↗
- Paper Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarc… DOI 10.1097/coc.0b013e31821a83d7↗
- Paper Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based c… DOI 10.1158/1535-7163.mct-11-0269↗
- Hye-Lim Jang · 2 shared papers, 2011–2025 · strength 0.29
- Jin Seok Heo · 1 shared paper, 2021 · strength 0.13
- In Woong Han · 1 shared paper, 2021 · strength 0.13
- Sang Hyun Shin · 1 shared paper, 2021 · strength 0.13
- Ho Yeong Lim · 3 shared papers, 2011–2018 · strength 0.13
- Paper Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. DOI 10.1186/s12885-018-4995-0↗
- Paper Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarc… DOI 10.1097/coc.0b013e31821a83d7↗
- Paper Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based c… DOI 10.1158/1535-7163.mct-11-0269↗
- Younak Choi · 1 shared paper, 2019 · strength 0.08
- Hye Jin Choi · 1 shared paper, 2019 · strength 0.08
- Kyu‐pyo Kim · 1 shared paper, 2019 · strength 0.08
- Kyung-Hun Lee · 1 shared paper, 2019 · strength 0.08
- Do‐Youn Oh · 1 shared paper, 2019 · strength 0.08
- Baek‐Yeol Ryoo · 1 shared paper, 2019 · strength 0.08
- Changhoon Yoo · 1 shared paper, 2019 · strength 0.08
- Jong Kyun Lee · 1 shared paper, 2012 · strength 0.03
- Hee Chul Park · 1 shared paper, 2012 · strength 0.03
- Seong Ho Choi · 1 shared paper, 2012 · strength 0.03
- Kyu Taek Lee · 1 shared paper, 2012 · strength 0.03
- Jun Ho Yi · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.